This study was designed to investigate the relationship between serum p53, tissue p53 and tissue permeability glycoprotein (P-gp) levels in gastric cancer. Serum levels of p53 were detected by enzymelinked immunosorbent assay, and tissue p53 and P-gp levels were analysed by immunohistochemistry. In total, 63.0% of gastric cancer tissue samples tested positive for P-gp and 58.7% of samples tested positive for p53. Tissue P-gp immunoreactivity was significantly correlated with tissue p53 immunoreactivity, and both tissue p53 and P-gp immunoreactivity were significantly correlated to the degree of cancer cell differentiation. The percentage of gastric cancer patients with serum positive for p53 was 36.2%, which was significantly higher than the rate in non-cancerous gastric disease patients. Serum p53 was significantly correlated to tissue p53 and tissue P-gp, inferring that the presence of p53 in the serum could indicate the status of tissue p53 and P-gp. This could, therefore, be useful for screening for the most appropriate (lowest toxicity and highest effectiveness) drugs to use ahead of (neo)-adjuvant chemotherapy.
Introduction
Gastric carcinoma is one of the most frequently occurring cancers, and is considered to be the fifth or sixth most common malignancy and the second leading cause of cancer death worldwide. 1, 2 Gastric cancer is declining in incidence in some large cities, but it remains the third most common malignancy among Chinese men and a significant cause of mortality. 3 Surgical resection is the only potentially curative treatment for gastric cancer, 4 and chemoradiotherapy or neo-adjuvant chemotherapy based on post-operative 5-fluorouracil (5-FU) (and its pro-drugs) has been used in order to try and improve treatment outcomes. 4 -6 Individualizing treatment, based on identifying patients who are sensitive or resistant to chemotherapeutic agents, leads to more effective treatment and a potential reduction in unpleasant drug-related side effects.
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Data on the correlation between molecular markers and response to chemotherapy are controversial, 7 although it has been reported that histological grading is a useful prognostic indicator in gastric cancer patients treated with neo-adjuvant chemotherapy. 8 Several investigators have demonstrated a correlation between overexpression of the p53 gene (evaluated using immunohistochemistry) in pretreatment endoscopic samples of primary gastric cancer and resistance to cisplatincontaining regimens. 9 -11 Thymidylate synthase (TS) gene expression seems to be related to response to chemotherapy. 6, 12, 13 Another gene potentially involved in chemoresistance, excision repair crosscomplementing-1 (ERCC-1), has been shown to be more highly expressed in nonresponsive gastric cancer patients than in responsive patients. 14 At present, however, there are no clinically accepted markers that can accurately predict the sensitivity or resistance of gastric cancer to particular chemotherapeutic agents.
The tumour suppressor protein p53 is a transcription factor that both activates the expression of genes containing the p53 binding site and represses the expression of some genes that lack this binding site. 15 Previous studies have shown that overexpression of wild-type p53 leads to apoptosis and cell cycle arrest. 16 Mutations in the p53 gene occur very frequently in many human cancers. In gastric carcinomas, the frequency of tumours that express mutant p53 varies from 4% to 71%, and aberrations of the p53 gene and overexpression of mutant forms of the protein are widely recognized markers of malignancy. 17 Permeability glycoprotein (P-gp), encoded by the multidrug resistance 1 (MDR1) gene, is a representative membrane efflux pump of the ATP-binding cassette transporters. 18, 19 These  proteins function as energy-dependent efflux  pumps for a variety of structurally diverse  chemotherapeutic  agents,  such  as  doxorubicin, vincristine, vinblastine, paclitaxel, colchicine, actinomycin D and mitomycin C, and can decrease the intracellular accumulation of these drugs. As a result, high levels of P-gp confer multidrug resistance (MDR) to cancer cells by evading the cytotoxic effects of chemotherapy drugs. 20, 21 In a previous study, 22 it was found that mutant p53 was related to MDR of the gastric cancer cell line SGC7901. In the present study, immunohistochemistry analysis was used to explore the relationship between p53 and P-gp levels in the tumour tissue of patients with gastric cancer, and between both tumour tissue p53 and P-gp levels and serum p53 levels, as measured by enzymelinked immunosorbent assay (ELISA). The aim of the present study was to evaluate whether serum p53 could be used as a marker to predict the sensitivity or resistance of gastric cancer to chemotherapeutic agents.
Patients and methods

PATIENTS
In this observational study, serum samples were obtained pre-operatively from patients with gastric cancer and from a group of similarly aged patients with non-cancerous gastric disease who were enrolled sequentially into the study following 
ENZYME IMMUNOASSAY FOR SERUM P53
Blood (3 ml) was collected from each patient before surgery and centrifuged at 1942 g for 10 min and the serum was collected and stored at -20°C until further analysis. Serum p53 levels were assessed using an ELISA kit for the detection of human p53 (Bender MedSystems, Vienna, Austria) according to the manufacturer's instructions.
HISTOPATHOLOGICAL ANALYSIS
The gastric cancer tissue samples were fixed in 10% formalin, then paraffin embedded and cut into sections of 4 µm. Tissue sections were stained with haematoxylin and eosin, and examined for histological classification by two expert investigators. Histological diagnosis and tumour stage were established according to the guidelines of the World Health Organization. 23 
IMMUNOHISTOCHEMICAL STAINING
Paraffin embedded 4 µm sections were subjected to immunohistochemical analysis using the EnVision ® Doublestain System (Dako, Glostrup, Denmark). Briefly, paraffin sections were de-waxed in xylene, rinsed in alcohol and further dehydrated in a graded alcohol series. The sections were then subjected to antigen retrieval treatment by boiling in 0.01 M citric acid, pH 6.0, for 5 min in a pressure cooker and then treated with 0.3% hydrogen peroxide for 30 min in absolute methanol to inhibit endogenous peroxidase. After antigen retrieval, the sections were blocked with diluted normal 1% fetal calf serum for 10 min at room temperature followed by incubation for 60 min with mouse monoclonal antibody against mutant p53 (clone DO-7, 1:200 dilution; Dako; CA, USA) or anti-P-gp (C494, Golden Bridge International; Mukilteo, WA, USA) at room temperature. The sections were then incubated with a horseradish peroxidase-conjugated secondary antibody from the EnVision ® Doublestain System, according to the manufacturer's instruction, and immunohistochemical staining was visualized using a standard streptavidinbiotin complex procedure, using 3-amino-9ethylcarbazole as substrate and Meyer's haematoxylin as a counterstain. Negative control reactions were performed in parallel without primary antibodies.
Immunohistochemical staining was evaluated by two pathologists using a multiheaded light microscope. Tissue samples were considered positive for p53 and P-gp if they showed staining for p53 in > 10% of the tumour cells (nuclear staining) and staining for P-gp in > 25% of tumour cells (cytoplasmic staining).
STATISTICAL ANALYSIS
Data are expressed as the frequency of patients or controls testing positive for serum p53, or tissue p53 and P-gp. Statistical analysis was performed using the SPSS ® statistical package, version 16.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Kappa tests or the χ 2 -test were applied to assess the statistical significance of the associations between serum p53 and tissue p53 immunoreactivity, serum p53 and tissue Pgp immunoreactivity, and between both tissue p53 and tissue P-gp immunoreactivity and cancer histology type. A P-value < 0.05 was considered to be significant.
Results
PATIENTS
Serum samples were obtained pre-p53 and gastric cancer response to chemotherapy operatively from 69 patients (45 men and 24 women) with gastric cancer, and from 52 patients with non-cancerous gastric disease (33 men and 19 women; including eight patients with chronic atrophic gastritis, 13 with chronic superficial gastritis, and 31 who were being investigated for gastric disease and were found to be healthy). The median age of the patients with gastric cancer was 58 years (range 33 -74 years), while the median age of the patients with noncancerous gastric disease was 39 years (range 25 -62 years). Gastric cancer tissues were available for immunochemical analysis from 46 of the 69 gastric cancer patients.
IMMUNOHISTOCHEMICAL ANALYSIS OF P53 AND P-GP IN GASTRIC CANCER TISSUE
Immunohistochemical staining for P-gp was identified mainly in the cytoplasm of malignant cells (Fig. 1A) . Out of the 46 patients, 29 (63.0%) showed immunoreactivity for P-gp in gastric cancer tissue. Immunostaining for p53 occurred in the nucleus of the cancer cells ( Fig. 1B ) and 27 out of 46 patients (58.7%) showed immunoreactivity for p53 in gastric cancer tissue. Table 1 shows the distribution of gastric cancer samples positive for p53 and P-gp relative to all cases of gastric cancer and by cancer histology. Neither p53 nor P-gp immunoreactivity in cancer tissue were significantly correlated to histological classification, age or sex of the patient. Cancer samples were further divided into well or moderately differentiated and poorly differentiated or undifferentiated tumours. Significantly more patients with well or moderately differentiated cancer tissue were immunoreactive for p53 (P = 0.013) and P-gp (P = 0.038) compared with those tissue samples that were poorly differentiated or undifferentiated. 
SERUM P53 LEVELS AND CORRELATION WITH TISSUE P53 AND P-GP
The concentration of pre-operative serum p53 ranged from 0.00 to 0.78 U/ml in the 52 patients with non-cancerous gastric disease and between 0.00 and 4.99 U/ml in the 69 patients with gastric cancer. To separate gastric cancer patients into those who were positive and those who were negative for serum p53, the mean serum concentration of p53 of patients with non-cancerous gastric disease plus two SDs was used as a cut-off value (0.36 U/ml). In this study, 25 out of the 69 (36.2%) patients with gastric cancer had serum p53 levels > 0.36 U/ml, whereas only three of the 52 (5.8%) patients with non-cancerous gastric disease had serum p53 levels > 0.36 U/ml; this difference was statistically significant (P < 0.001). Of the 27 gastric cancer patients with tissue samples positive for p53, 23 (85.2%) were also positive for P-gp and 18 (66.7%) patients also had serum samples positive for p53 (> 0.36 U/ml). Both the serum p53 immunoreactivity and tissue P-gp immunoreactivity were significantly correlated to tissue p53 immunoreactivity (P < 0.001 in both cases). Serum p53 immunoreactivity was also significantly correlated with tissue P-gp immunoreactivity (P = 0.022). Kappa tests also confirmed that the serum p53, tissue p53 and tissue P-gp levels were highly correlated ( Table 2 ).
Discussion
Surgical resection of the primary tumour and regional lymph nodes is the treatment of choice for gastric cancer. Despite complete resection, patients can subsequently present with local disease, peritoneal carcinomatosis, or distant metastases. Thus, adjuvant chemotherapy after the operation has been considered necessary to eliminate systemic strategies have been investigated with the intent of treating microscopic residual disease post-operatively. 1 Unfortunately, the adjuvant treatment strategy has produced disappointing results due to the MDR of malignant cells to a range of chemotherapeutic agents. 1 Thus, MDR presents a considerable challenge in cancer treatment. At present, there is a need for tumour markers to identify patients who will be sensitive or resistant to chemotherapeutic agents, thereby allowing a rationale for an effective choice of treatment.
In a previous study we found that the gastric cancer cell line SGC7901, which expresses mutant p53, showed higher chemotherapeutic resistance to 5-FU and doxorubicin but not to cisplatin. 22 Mutant p53 activates the MDR1 gene which, in turn, increases the production of MDR1 mRNA. Thus, the functional status of p53 in human gastric cancer cell lines directly affects their sensitivity to chemotherapeutic agents.
In the present study, the protein levels of p53 and P-gp in 46 gastric cancer tissue samples were measured; 63.0% of gastric cancer tissue samples were positive for P-gp and 58.7% of samples were positive for p53. Neither tissue p53 nor P-gp immunoreactivity were significantly correlated with the histological classification of the tumour, or to the sex or age of the patient, but both were significantly correlated to the degree of differentiation of the tumour sample. The percentages of patients who had tissue samples positive for p53 and P-gp were higher in moderately and well differentiated tumour samples compared with those that were poorly differentiated or undifferentiated. Tissue P-gp levels were significantly correlated to tissue p53 levels.
Several research groups have investigated TS, p53, vascular endothelial growth factor (VEGF), Bcl-2, and the MDR-related proteins, P-gp, glutathione S-transferases (GST-π), topoisomerase-II (Topo-II) and lung resistance protein (LRP) as potential biological markers to predict the chemotherapeutic response of gastric cancer. 6,24 -26 Boku et al. 24 reported that the number of favorable phenotypes (≥ 4 versus ≤ 3) of the markers VEGF + , p53 -, Bcl-2 -, TSand GST-πwas prognostic for the outcome of advanced gastric cancer treatment with cisplatin. The VEGF + phenotype has a different impact on survival following treatment with 5-FU and cisplatin. 24 Kamoshida et al. 6 demonstrated that high expression of TS and/or p53 in pre-treatment biopsy specimens predicted chemoresistance to a combination of S-1 and cisplatin in gastric cancer. Shi et al. 25 reported that combined determination of MDR-related proteins P-gp, GST-π, Topo-II and LRP may be prospectively valuable for optimizing chemotherapy regimens.
All of the above results have been based on analysis of cancer tissue. The question of how to evaluate cancer biomarker status without having a tissue sample remains to be addressed. The ELISA assay described in the present study does not require a tissue specimen and is easy to perform. Mutation in the p53 gene in cancerous tissue leads to the accumulation of mutant p53 in the tumour tissue, together with increases in mutant p53 in the serum. 27, 28 Thus an analysis of serum concentrations of p53 antigen using ELISA might potentially be a useful marker for malignancy. The percentage of gastric cancer patients who were positive for serum p53 was significantly higher than for those patients with non-cancerous gastric disease who were positive for serum p53. Correlation analyses between serum p53 and tissue p53 and tissue P-gp showed that serum p53 immunoreactivity was significantly correlated with tissue p53 and P-gp immunoreactivity. It is possible that some tumours expressing p53 may not release enough p53 into the circulation to be detectable in serum samples, which might explain why the percentage of serum samples positive for p53 was lower than those tissue samples that were positive for p53. Nevertheless, serum p53 immunoreactivity could be used to indicate the status of p53 and P-gp expression in tumour tissues for some patients. Previous studies have shown, in tumours other than gastric cancer, that serum levels of p53 are reasonably accurate in reflecting an alteration in tissue p53 expression in tissues at the gene and/or protein level. 28 -30 In conclusion, positive tissue expression of both p53 and P-gp was found to be significantly correlated to the degree of cancer differentiation and there was a significant correlation between tissue P-gp and p53 levels. Serum p53 immunoreactivity was also significantly correlated with tissue p53 and P-gp and potentially may be useful in indicating the status of p53 and P-gp expression in tumour tissue. The presence of p53 in the serum could, therefore, provide a valuable means of screening for the most appropriate drugs, i.e. those with low toxicity and high effectiveness, ahead of (neo-) adjuvant chemotherapy and for optimizing individualized chemotherapy regimens. Further study is necessary to explore the relationship between serum and tissue p53 and P-gp, and the response to chemotherapy, in order to predict and overcome MDR.
